FARMINGDALE, N.Y., Aug. 12, 2011 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a medical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for wound debridement, spinal surgery, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications, has entered into a new three-year exclusive distribution agreement with MD Solutions Australasia Pty. Ltd., based in Newport, Victoria, Australia. MD Solutions will sell and distribute the BoneScalpel™ Ultrasonic Bone Cutter throughout Australia and New Zealand. The agreement with MD Solutions includes annual minimum purchase requirements.
MD Solutions is a premier distributor of high tech, state-of-the-art medical devices to the Australian/NZ market and is widely known for their commitment to excellence in customer service and their ability to introduce new products. MD Solutions is highly experienced in marketing surgical devices and focuses on spine surgery, neurosurgery and other skull based procedures.
The BoneScalpel is a tissue specific osteotomy device capable of making precise cuts through bone and hard tissue while largely preserving delicate soft tissue structures. The BoneScalpel offers the convenience and speed of a power instrument while minimizing the potential risks associated with rotary sharps.
"Misonix is pleased to add MD Solutions to our growing distribution network in Asia and the South Pacific. Their reputation as a quality distributor of medical equipment and devices in Australia and New Zealand is well known to us," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "Their success in introducing new medical devices, as well as their commitment to customer service, weighed heavily in the distributor selection process."
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact:
Kevin McGrath/Cameron Associates, Inc.
|SOURCE Misonix, Inc.|
Copyright©2010 PR Newswire.
All rights reserved